News
PAVMZ
0.0201
-33.00%
-0.0099
Weekly Report: what happened at PAVMZ last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at PAVMZ last week (0408-0412)?
Weekly Report · 04/15 10:30
PAVMED INC <PAVM.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $26 FROM $30
Reuters · 04/15 03:04
Weekly Report: what happened at PAVMZ last week (0401-0405)?
Weekly Report · 04/08 10:34
Weekly Report: what happened at PAVMZ last week (0325-0329)?
Weekly Report · 04/01 10:33
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
The Dow Jones Industrial Average was up 0.72% on Wednesday. Merck & Co hit record high as FDA approves therapy for rare lung condition. Reddit Inc up 46% in fifth day of trading. Netflix, Reddit, Stoke Therapeutics are among the day's top stocks.
Reuters · 03/27 17:45
PAVmed Non-GAAP EPS of -$1.33 beats by $0.47, revenue of $1.05M beats by $0.02M
Earnings News PAVmed Non-GAAP EPS of -$1.33 beats by $0.47, revenue of $1.05M beats by £0.02M. PAvmed had cash and cash equivalents of $19.6 million as of December 31, 2022.
Seeking Alpha · 03/27 04:53
Pavmed Inc: Annual report
Press release · 03/25 22:59
Lucid Diagnostics Inc reports results for the quarter ended in December - Earnings Summary
Lucid Diagnostics Inc reports results for the quarter ended in December. Revenue rose 828.6% to $1.04 million from a year ago. The company reported a quarterly loss of $10.83 million. Lucid Diagnostic Inc shares had fallen by 22.7% this quarter.
Reuters · 03/25 22:19
Weekly Report: what happened at PAVMZ last week (0318-0322)?
Weekly Report · 03/25 10:35
Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lucid Diagnostics Inc expected to post a loss of 26 cents a share. The company is expected to report a 840.9% increase in quarterly revenue to $1.054 million. The average analyst estimate for the company is for a quarterly loss of 26 cents per share.
Reuters · 03/22 20:45
PAVmed Inc <PAVM.OQ> expected to post a loss of $1.89 a share - Earnings Preview
PAVmed Inc expected to post a loss of $1.89 a share. The company is expected to report a 835.7% increase in quarterly revenue. The average analyst estimate for PAVmed's quarterly revenue is for a rise of 8.7%.
Reuters · 03/22 20:05
Weekly Report: what happened at PAVMZ last week (0311-0315)?
Weekly Report · 03/18 10:34
Weekly Report: what happened at PAVMZ last week (0304-0308)?
Weekly Report · 03/11 10:31
Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lucid Diagnostics Inc expected to post a loss of 26 cents a share. The company is expected to report a 840.9% increase in quarterly revenue to $1.054 million. LSEG's mean analyst estimate for the company is for a quarterly loss of 26 cents per share.
Reuters · 03/08 21:14
Weekly Report: what happened at PAVMZ last week (0226-0301)?
Weekly Report · 03/04 10:34
Weekly Report: what happened at PAVMZ last week (0219-0223)?
Weekly Report · 02/26 10:42
Weekly Report: what happened at PAVMZ last week (0212-0216)?
Weekly Report · 02/19 10:44
Weekly Report: what happened at PAVMZ last week (0205-0209)?
Weekly Report · 02/12 10:36
Weekly Report: what happened at PAVMZ last week (0129-0202)?
Weekly Report · 02/05 10:42
More
Webull provides a variety of real-time PAVMZ stock news. You can receive the latest news about Pavmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About PAVMZ
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.